Perelman School of Medicine at the University of Pennsylvania

Center for Research on Reproduction and Women's Health

Andrea Facciabene

faculty photo
Research Assistant Professor of Radiation Oncology
Department: Radiation Oncology

Contact information
University of Pennsylvania Perelman School of Medicine
Department of Radiation Oncology
Smilow Center for Translational Research Rm. 8-133
3400 Civic Center Blvd., Bldg 421
Philadelphia, PA 19104
Office: 215-746-7071
Fax: 215-898-0090
Education:
BS (Pharmaceutical Biotechnology Science (summa cum laude))
University of Bologna, Italy (Thesis: Centre of Drug Discovery, L'Aquila, Italy) Summa Cum Laude, 2000.
PhD (Cancer Rsrch & Molecular Biol & Biotechnology)
Univ of Perugia in collaboration with the Univ of California San Diego, San Diego, CA (coursework 11/01-5/05 in Italy; exam in CA 2/06), 2006.
Post-Graduate Training
Research Fellowship, Gene Therapy, IRBM, Istituto Ricerche Biologie Medicina-P. Angeletti (Merck & Co) Rome, Italy (Feb, 00 to Nov, 01) , 2000-2002.
Postdoctoral Research Fellowship, University of California San Diego, Department of Cancer Research San Diego, CA (5/05 - 5/06) • Development of MUC1 cancer vaccine , 2005-2006.
Postdoctoral Research Fellowship, University of Pennsylvania, Center for Ovarian Cancer Research 5/06-8/07 , 2006-2007.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Dr. Andrea Facciabene’s laboratory is focussed on immunotherapy and investigation of the network of immune responses to tumors, combining basic research and clinical investigation. Our goals are to advance understanding of tumor immunology and to use new findings to develop efficacious new therapies. Our basic research includes the development of two new vaccination strategies: one uses mitochondria isolated from tumors, the other utilizes new tumor vasculature antigen. We also study regulation of immune surveillance and the tumor microenvironment by the gut microbiome. Our clinic research includes the development of new preclinical immunotherapies.

Selected Publications

Monk BJ, Facciabene A, Brady WE, Aghajanian C, Fracasso PM, Walker J, Lankes HA, Manjarrez KL, Danet-Desnoyers G, Bell-McGuinn KM, McCourt CK, Malykhin A, Hershberg RM, Coukos G: Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemo-immunotherapy. Clin Cancer Res. AACR, 23(8): 1955-1966, April 2017.

Stavros R, Mireia Uribe-HErranz, Pierini S, Costas Koumenis, Facciabene A: The impact of Gut microbiome on the antitumor effects of Radiotherapy. AACR, Washington DC Apr 2017.

Facciabene A, De Sanctis F, Pierini S, Reis E, Balint K, Router J, Facciponte J, De Angelis R, Magotti P, Lambris J, Coukos G.: Local Endothelial Complement Activation Reverses Endothelial Quiescence, Enabling T-cell Homing and Tumor Control during T-cell Immunotherapy. Oncoimmunology 2017.

Herranz MU, Mennuni C, La Nicola M, Facciabene A: mTERT genetic vaccine combined with chemotherapy augments antigen-specific immune response and confers tumor protection in time depended fashion. Society for Immunotherapy of Cancer, National Harbor, MD Nov 2016.

Pierini S, Chungyun F, Stavros R, Facciabene A: A Tumor Mitochondria Vaccine Protects against Experimental Renal Cell Carcinoma. Society for Immunotherapy of Cancer, National Harbor, MD Nov 2016.

Pierini S, Fang C, Rafail S, Facciponte JG, Huang J, De Sanctis F, Morgan MA, Uribe-Herranz M, Tanyi JL, Facciabene A*: A Tumor Mitochondria Vaccine Protects against Experimental Renal Cell Carcinoma. J Immunol 195(8): 4020-7, Oct 2015 Notes: *Corresponding Author.

Ugel S, Facciponte JG, De Sanctis F, Facciabene A*: Targeting tumor vasculature: expanding the potential of DNA cancer vaccines. Cancer Immunol Immunother 64(10): 1339-48, Oct 2015 Notes: *corresponding author.

Facciponte JG, Ugel S, De Sanctis F, Li C, Wang L, Nair G, Sehgal S, Raj A, Matthaiou E, Coukos G, Facciabene A*: Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature. J Clin Invest 124(4): 1497-511, Apr 2014 Notes: *Corresponding Author.

Pierini S, Chungyun F, Stavros R, Facciabene A: A Tumor Mitochondria Vaccine Protects against Experimental Renal Cell Carcinoma. Translational Research in Mitochondria, Aging and Diseases TRiMAD Mar 2014.

Herranz MU, Mennuni C, La Nicola M, Facciabene A: mTERT genetic vaccine combined with chemotherapy augments antigen-specific immune response and confers tumor protection in time depended fashion. Translational Research Cancer Centers Consortium, Seven Spring PA Feb 2014.

back to top
Last updated: 05/25/2017
The Trustees of the University of Pennsylvania